Table 3.
Responses to treatment and outcomes in both cohorts.
| PP cohort N = 27 |
CT cohort N = 44 |
P | |
|---|---|---|---|
| Flare up effect | 0 (0%) | 5 (11%) | ns |
| Best response to treatment | |||
| Complete response | 10 (37%) | 21 (48%) | ns |
| Partial response | 11 (41%) | 14 (32%) | ns |
| Stable disease | 6 (22%) | 4 (9%) | ns |
| Persistence of biological activity after treatment | 10 (37%) | 8 (18%) | ns |
| Median TTNT (months) | 17.7 | 11 | 0,02 |
| Median OS (months) | 128,4 | Nr | ns |
Best response to treatment was defined as the response achieved after rituximab therapy according to biological and clinical evaluation. OS: overall survival; TTNT: time to next treatment; ns: not significant.